Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

##STR00001##

The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.

The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.

The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.

The present invention provides an industrially advantageous production method of (1R,2S)-2-{[((2,4-dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide. (1R,2S)-2-{[((2,4-Dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (compound [A]) is produced by an industrially advantageous method by a route via a novel compound. ##STR00001##
wherein each symbol is as described in the description.

The present invention provides an industrially advantageous production method of (1R,2S)-2-{[((2,4-dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide. (1R,2S)-2-{[((2,4-Dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (compound [A]) is produced by an industrially advantageous method by a route via a novel compound. ##STR00001##
wherein each symbol is as described in the description.

The present invention provides a compound useful as a synthetic intermediate for an anti-HIV agent having an integrase inhibitory activity, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate. Specifically, for example, a compound represented by the formula (2):

##STR00001##

wherein R is a fluorine atom or a methoxy group, and R.sup.400 is a hydrogen atom or a C.sub.1-C.sub.4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate.

The present invention provides a compound useful as a synthetic intermediate for an anti-HIV agent having an integrase inhibitory activity, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate. Specifically, for example, a compound represented by the formula (2):

##STR00001##

wherein R is a fluorine atom or a methoxy group, and R.sup.400 is a hydrogen atom or a C.sub.1-C.sub.4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate.

The present invention relates to derivatives of dehydroabietic acid useful in treatment of cardiac arrhythmia or a hyperexcitablity disease, such as epilepsy or pain, by extracellularly acting on the voltage sensitive domain (VSD) to open at least one member of the family of voltage-gated Kv (potassium) channels.

The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.